EPS for Soligenix, Inc. (SNGX) Expected At $-0.28

August 9, 2018 - By Ash Maslow

Soligenix, Inc. (NASDAQ:SNGX) Logo

Analysts expect Soligenix, Inc. (NASDAQ:SNGX) to report $-0.28 EPS on August, 10.They anticipate $0.13 EPS change or 31.71 % from last quarter’s $-0.41 EPS. After having $-0.27 EPS previously, Soligenix, Inc.’s analysts see 3.70 % EPS growth. The stock increased 7.30% or $0.1 during the last trading session, reaching $1.47. About 1.84 million shares traded or 955.83% up from the average. Soligenix, Inc. (NASDAQ:SNGX) has declined 32.77% since August 9, 2017 and is downtrending. It has underperformed by 45.34% the S&P500.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $25.99 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

More news for Soligenix, Inc. (NASDAQ:SNGX) were recently published by: Streetinsider.com, which released: “Soligenix, Inc. (SNGX) Appoints Mark Pearson to Board” on July 24, 2018. Seekingalpha.com‘s article titled: “Soligenix issues an update for development programs” and published on July 19, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.